glp-1 in obesity Simplified summary of the biological actions of GIP and as Nutritional priorities to support GLP-1

In clinical trials of Tirzepatide, a dual-acting GLP-1 and GIP agonist currently prescribed for Type 2 diabetes, obese patients lost 21 percent body mass in 1.4 years, surpassing the 15 percent reduction seen with Semaglutide

10.4103/jod.jod_78_22 26 EbiaiR.GoreJ.KaptenB

GLP-1 and GIP stimulate insulin secretion from these cells in a glucose-dependent manner, meaning that insulin release intensifies in response to heightened plasma glucose levels

whilst some studies suggest potential benefits for skin elasticity and hydration, the evidence base remains modest and further research is needed to establish definitive recommendations